Denali Therapeutics (DNLI) EBIT Margin (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly EBIT Margin of 8981.45% for Q3 2023, down 579668.0% year-over-year from N/an in Q3 2022, and down 15595.1% quarter-over-quarter from 57.96% in Q2 2023.
Denali Therapeutics (DNLI) EBIT Margin (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported EBIT Margin for 6 consecutive years, with 8981.45% the latest figure, recorded in Q3 2023.
- In Q3 2023, EBIT Margin fell 579668.0% year-over-year to 8981.45%; the TTM figure through Jun 2024 stood at 37938.04% (down 3789042.0% YoY), while the FY2023 annual figure was 59.51%, up 26481.0% from the prior year.
- EBIT Margin fell to 8981.45% in Q3 2023 per DNLI's latest filing, from 57.96% in the prior quarter.
- Across five years, EBIT Margin topped out at 77.04% in Q4 2020 and bottomed at 115321.15% in Q1 2020.
- Historically, EBIT Margin has averaged 7301.99% across 5 years, with a median of 1010.89% in 2019.
- Annual changes were most pronounced in 2020 — EBIT Margin plunged 11431026 bps — and 2021, when it surged 11442214 bps.
- Denali Therapeutics' EBIT Margin stood at 1236.26% in 2019, then soared by 106 bps to 77.04% in 2020, then plunged by 306 bps to 158.51% in 2021, then tumbled by 565 bps to 1053.44% in 2022, then tumbled by 753 bps to 8981.45% in 2023.
- Business Quant data shows DNLI's EBIT Margin at 8981.45% in Q3 2023, 57.96% in Q2 2023, and 343.8% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -3,622.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,622.11% |
| Sep 30, 2023 | -8,981.45% |
| Jun 30, 2023 | 57.96% |
| Mar 31, 2023 | -343.80% |
| Dec 31, 2022 | -1,053.44% |
| Sep 30, 2022 | -3,184.77% |
| Jun 30, 2022 | -117.03% |
| Mar 31, 2022 | -157.80% |
| Dec 31, 2021 | -158.51% |
| Sep 30, 2021 | -1,619.55% |
| Jun 30, 2021 | -412.11% |
| Mar 31, 2021 | -899.02% |
| Dec 31, 2020 | 77.04% |
| Sep 30, 2020 | -640.35% |
| Jun 30, 2020 | -1,054.50% |
| Mar 31, 2020 | -115,321.15% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -1,150.62% |
| Jun 30, 2019 | -1,531.55% |
| Mar 31, 2019 | -1,010.89% |